AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
JMCP Outsert - CLL (Health Plan)
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin. View a patient case study and treatment plan that was discussed through the AMCP Marketing Insights Program.
For more disease state research, view the Market Insights Program.
Related
To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.
To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
